Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Lai AY., et al.
Journal for ImmunoTherapy of Cancer
October 2020
Authors and Affiliates
Anne Y Lai 1, Jessica A Sorrentino 2, Konstantin H Dragnev 3, Jared M Weiss 4, Taofeek K Owonikoko 5, Julie A Rytlewski 6, Jill Hood 6, Zhao Yang 1, Rajesh K Malik 1, Jay C Strum 1, Patrick J Roberts 1; 1 Research and Development, G1 Therapeutics, Inc, Research Triangle Park, North Carolina, USA. 2 Research and Development, G1 Therapeutics, Inc, Research Triangle Park, North Carolina, USA jsorrentino@g1therapeutics.com. 3 Department of Hematology and Oncology, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. 4 Division of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA. 5 Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA. 6 Life Sciences Research, Adaptive Biotechnologies Corp, Seattle, Washington, USA.